Current trends in management of hepatitis B virus reactivation in the biologic therapy era

Hepatitis B virus (HBV) reactivation represents an emerging cause of liver disease in patients undergoing treatment with biologic agents. In particular, the risk of HBV reactivation is heightened by the use monoclonal antibodies, such as rituximab (anti-CD20) and alemtuzumab (anti-CD52) that cause p...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Mastroianni, Claudio M, Lichtner, Miriam, Citton, Rita, Borgo, Cosmo Del, Rago, Angela, Martini, Helene, Cimino, Giuseppe, Vullo, Vincenzo
Natura: Artigo
Lingua:Inglês
Pubblicazione: Baishideng Publishing Group Co., Limited 2011
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3198017/
https://ncbi.nlm.nih.gov/pubmed/22025876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v17.i34.3881
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi